The effects of docetaxel, platinum, and fluorouracil (TPF) induction chemotherapy plus concurrent chemoradiotherapy (CCRT) on locoregionally advanced nasopharyngeal cancer (NPC) are unclear. This study examined the long-term outcomes of the addition of this regimen to CCRT for stage III and IVA/B NPC. METHODS: Two parallel, single-arm phase 2 trials were performed synchronously to evaluate the efficacy and toxicity of TPF-based induction chemotherapy in patients with stage III or IVA/B NPC. The induction chemotherapy, which preceded standard intensity-modulated radiation therapy/platinum-based chemoradiation, consisted of 3 cycles of docetaxel (75 mg/m 2 on day 1), cisplatin (75 mg/m 2 on day 1), and a continuous infusion of fluorouracil (500 mg/m 2 /d on days 1-5) every 4 weeks. The primary endpoint for both trials was 5-year overall survival (OS). RESULTS: Between January 2007 and July 2010, 52 eligible patients with stage III NPC and 64 eligible patients with nonmetastatic stage IV NPC were accrued to the 2 trials. With a median follow-up of 67 months, the 5-year OS, progression-free survival, distant metastasis-free survival, and local progression-free survival (LPFS) rates were all improved in comparison with historical benchmarks for patients with stage III or IVA/ IVB NPC. Multivariate analyses indicated that T and N classifications (T1/T2 vs T3/T4 and N3 vs N0-N2) were the only significant prognosticators for OS. The number of induction chemotherapy cycles was the only significant prognostic factor for predicting LPFS. CONCLUSIONS: TPF-based induction chemotherapy appears to significantly improve outcomes in comparison with historical data when it is administered before CCRT for locoregionally advanced NPC. A phase 3 trial is currently being performed to confirm this benefit.
INTRODUCTION
The use of concurrent chemoradiation has significantly improved the treatment outcomes, including overall survival (OS), for patients with locally advanced nasopharyngeal cancer (NPC). [1] [2] [3] [4] With the local failure rate reduced to less than 10% with the prevailing use of intensity-modulated radiation therapy (IMRT), distant metastases have become the most important mode of treatment failure. Because the majority of patients present with locally advanced disease (defined as a tumor classification of T3/T4 or N1) in the endemic area, approximately 15% to 20% of these patients will suffer from distant failure even with aggressive treatment using concurrent IMRT and chemotherapy. 5 The effectiveness of adjuvant or induction chemotherapy in NPC has been studied extensively in phase 3 randomized trials and in a number of meta-analyses. 1, [6] [7] [8] The literature published thus far has not confirmed the effectiveness of platinum-or fluorouracil-based adjuvant chemotherapy, used alone or after concurrent chemoradiotherapy (CCRT), for the OS of patients with locally advanced NPC. The benefit of induction chemotherapy with cisplatin (with or without 5-fluorouracil) appears to be limited to disease-free survival (DFS) or cancer-specific survival. Clearly, a more effective chemotherapy regimen is needed to further improve patients' survival.
The improvement of the effectiveness of induction chemotherapy with cisplatin with or without 5-fluorouracil due to the addition of a taxane (ie, docetaxel and platinum [TP] or docetaxel, platinum, and fluorouracil [TPF] ) for patients with locally advanced head and neck squamous cell carcinoma has been well reported in several randomized phase 3 trials. [9] [10] [11] It is reasonable to postulate that such synergistic effects are equally beneficial to patients with locally advanced NPC. As such, we initiated 2 single-arm phase 2 trials to evaluate the efficacy of TPFbased induction chemotherapy against locally advanced NPC. Two separate single-arm phase 2 trials for stage III and stage IVA/B, instead of one for both stages, were designed because of the substantial differences in outcomes previously reported in the literature in terms of the OS and progression-free survival (PFS) rates as well as the mode of treatment failure between stage III NPC and stage IVA/B NPC. Despite the expected differences, the interim 3-year OS, PFS, and distant metastasis-free survival (DMFS) rates from our trials were nearly identical for stage III and IVA/B NPC. 12 In addition, they were highly consistent with those reported in another randomized phase 2 trial with a limited sample size. 13 These highly consistent preliminary results suggested the potential benefits of induction TPF for the treatment of locally advanced NPC. However, long-term results for the efficacy of TP-based induction chemotherapy for NPC have never been reported in any prospective studies. Here we report the final outcomes of our 2 single-arm phase 2 TPF trials.
MATERIALS AND METHODS

Participants
Between January 2007 and July 2010, we performed 2 single-arm phase 2 clinical trials for stage III NPC and stage IVA/IVB NPC, respectively (American Joint Committee on Cancer staging system, 7th edition). In addition to the stages at diagnosis, eligible patients were 18 to 70 years old with nonmetastatic, histologically confirmed nonkeratinizing NPC and had an expected lifespan of at least 6 months and Karnofsky scores of at least 70. All patients had adequate bone marrow, hepatic, and renal function before the treatment.
Exclusion criteria included the following: previous chemotherapy, radiation therapy, or definitive surgery to the head and neck for any conditions; NPC of a pathology type other than World Health Organization type 2 or 3; a history of any other type of malignancy except for basal cell carcinoma of the skin; pregnancy or lactation; unstable cardiac disease needing treatment; an active and uncontrolled infection; and a mental disorder influencing a patient's judgment about participating in the trial. These trials were approved by the ethics committee of the Fudan University Shanghai Cancer Center, and all participants provided written informed consent.
Pretreatment Evaluation
A histological diagnosis of the primary disease was required for all patients. Other pretreatment evaluations included a complete history and physical examination with an emphasis on the head and neck area, a complete blood count, a serum biochemical profile, and liver/renal function tests. A magnetic resonance imaging (MRI) scan of the head and neck was required for all patients unless clinically contraindicated. A thoracic computed tomography (CT) scan, an abdominal CT scan or sonography, and a whole-body bone scan were also required unless optional whole-body positron emission tomography/CT was performed.
Chemotherapy
The studied neoadjuvant chemotherapy regimen called for 3 cycles of TPF every 3 weeks. Each cycle of chemotherapy consisted of docetaxel (75 mg/m 2 on day 1), cisplatin (75 mg/m 2 on day 1), and 5-fluorouracil (2500 mg/m 2 as an intravenous infusion over the course of 120 hours). A 20% reduction in the docetaxel dose with constant cisplatin and 5-fluorouracil doses was allowed if a grade 4 hematologic adverse event or febrile neutropenia emerged during the previous course, and 5-fluorouracil was stopped if higher than grade 3 mucositis or diarrhea occurred during the former course. Recombinant granulocyte colony-stimulating factor support was permitted for prophylaxis, and antibiotic therapy was used when patients had grade 4 neutropenia.
The concurrent chemotherapy regimen consisted of weekly cisplatin (40 mg/m 2 ) during radiotherapy for a maximum of 7 cycles, which began on the first day of radiotherapy as planned. No adjustment of concurrent chemotherapy was to be allowed under any circumstances except for the following: the initiation of chemotherapy could be postponed if the neutrophil count dropped to <2000/lL or the platelet count was <100,000/lL. Chemotherapy could be suspended if the creatinine clearance rate became <50 mL/min.
Radiation Therapy
All patients in both trials received IMRT except for 15 patients (7 with stage III NPC and 8 with stage IVA/B NPC) who received 3-dimensional conformal radiotherapy because of the unavailability of an IMRT facility at the time of the initiation of their radiation therapy. The gross tumor volume (GTV) and the clinical target volume (CTV) were defined previously.
14 Briefly, the GTVs of both the primary and the neck metastasis (lymph nodes) were defined as all gross lesions observed in clinical and imaging examinations. The high-risk CTV consisted of a 5-mm margin surrounding the GTV, the entire nasopharyngeal cavity, the anterior clivus (the whole clivus if invaded), the skull base, the pterygoid plates, the parapharyngeal space, the inferior sphenoid sinus (the whole sphenoid sinus had to be covered for T3 and T4 disease), the posterior of the nasal cavity and the maxillary sinus, and the upper nodal region, including retropharyngeal lymph nodes and levels II, III, and Va. Level Ib had to be included in the high-risk CTV for patients who had metastatic lymph nodes at level IIa and any lymph node drainage pathways that contained metastatic lymph nodes. The low-risk CTV included level IV and Vb nodal regions in patients without metastatic cervical lymph nodes. A minimum of 5 mm around the GTV of the primary, a minimum of 3 mm around the GTV of the neck metastasis (lymph nodes), and CTVs were added in all directions to create each respective planning target volume (PTV): gross PTV, lymph-node PTV, high-risk PTV, and low-risk PTV.
The dose of IMRT prescribed for the gross PTV, lymph-node PTV, high-risk PTV, and low-risk PTV were 70, 68.25, 66.50, and 61.25 Gy (in 35 fractions), respectively. The low neck and supraclavicular area was irradiated with anteroposterior/posteroanterior fields to a total of 54 Gy in 30 fractions. Radiation was delivered once per day in 5 fractions per week over the course of 7 weeks. Twenty patients (6 in stage III and 14 in stage IVA/B) received boost irradiation doses of 4 to 6 Gy in 2 or 3 fractions to the residual tumors in the postnasal space or the neck. The use of boost irradiation was at the discretion of the attending radiation oncologists and was based on the resolution of the gross disease toward the end of the radiation therapy.
Follow-Up
After the completion of their treatment, all patients were reviewed every 3 months during the first 3 years, every 6 months for the following 2 years, and annually thereafter. Local recurrences were confirmed histologically or through imaging studies using MRI. Regional recurrences detected by a clinical examination of the neck were confirmed by MRI of the neck or histologically with fineneedle aspiration. Distant metastases were diagnosed by clinical examinations, including imaging studies. Salvage treatments, including re-irradiation, chemotherapy, and surgery, were recommended for patients who had developed a recurrence when possible.
Statistical Analysis
The primary endpoint for both trials was the 5-year OS rate. Secondary endpoints included 5-year PFS, local progression-free survival (LPFS), regional progressionfree survival (RPFS), and DMFS rates. All survival times were measured from the point of patient accrual to either death or the date of the last follow-up for patients who remained alive (they were censored). The estimated OS, PFS, LPFS, RPFS, and DMFS rates were calculated with the Kaplan-Meier method. Comparisons between the 2 trials for the outcome parameters with a log-rank test were planned during the design of the trials.
At the time of the study design in 2006, 5-year OS data after concurrent IMRT and chemotherapy or locally advanced NPC were not available. The baseline 5-year OS rates of 65% and 45% for stage III and IVA/IVB NPC were reported in prospective trials that used conventional radiotherapy. 15, 16 Two trials were designed because the reported baseline OS rates differed substantially between the 2 stages. The trials presented in this report were designed with a power of 80% and a type I error rate of .05 (1-sided) to detect an improvement of 20% in the 5-year OS rates to 85% and 65% from 65% and 45% for stage III NPC and stage IVA/IVB NPC, respectively, with the addition of induction chemotherapy to concurrent chemoradiation. Forty-seven patients and 58 patients were needed for the stage III trial and the stage IVA/IVB trial, respectively. The accrual of 52 and 64 patients was planned under the assumption that 10% of the patients might drop out or be lost to follow-up from the studies or experience a substantial protocol violation. However, recently reported 5-year OS rates after IMRT plus concurrent chemotherapy but without induction chemotherapy were in the range of 65% to 75% for patients with stage III to IVB NPC combined, and no segregated OS rates were available for the 2 stages. 17, 18 Our original total sample size of 116 patients was sufficient to detect an improvement of 15% (from 70% to 85%) in OS with a type I error rate of .05 and a power of 80%. 19 
RESULTS
Patient Characteristics
Between January 2007 and July 2010, 52 and 64 eligible patients were recruited into these 2 prospective phase 2 trials for stage III NPC and stage IVA/B NPC, respectively. Regular follow-up until death or the latest scheduled assessment was performed for all patients who joined the trials.
The patients' characteristics and staging are detailed in Table 1 . The 2 trials were well balanced in terms of baseline demographic and clinical characteristics except for the stage of the disease at diagnosis (Table 1) .
OS
With a median follow-up time of 66.8 months (range, 15.9-105.4 months) for both trials, the 5-year OS, PFS, LPFS, and DMFS rates for the entire cohort of patients from both trials were 87.0%, 74.4%, 89.8%, and 92.9%, respectively. Table 2 lists the 3-, 5-, and 7-year estimated rates for OS, PFS, LRFS, RPFS, and DMFS for all patients included in the 2 trials. Kaplan-Meier curves for OS and PFS are provided in Figures 1 and 2 , respectively. A total of 19 patients died: 16 deaths were due to the progression of the disease, 1 death was due to treatmentinduced mucosal necrosis, and 2 deaths were due to other medical conditions. The planned comparison of the 2 trials revealed no significant differences in any endpoints, including OS rates, between patients with stage III NPC and patients with stage IVA/IVB NPC. However, a trend was observed in OS and PFS. The 5-year OS rates were 91.6% and 83.1% (P 5 .059) and the 5-year PFS rates were 80.1% and 66.8% (P 5 .072) for stage III NPC and stage IVA/B NPC, respectively (Table 3) .
Treatment Compliance and Toxicity
All patients completed at least 2 courses of neoadjuvant chemotherapy, and 103 patients (88.8%) completed 3 planned courses. Seventy-seven (66.4%), 23 (19.8%), and 16 patients (13.8%) completed 5 to 7, 4, or 1 to 3 courses of concurrent chemotherapy, respectively (median, 5 courses). Adverse events were evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0). Acute adverse events that occurred during neoadjuvant chemotherapy and CCRT were detailed previously. 12 As for late toxicities, 10 patients (8.6%) developed grade 2 or 3 xerostomia. Grade 2 and 3 hearing loss occurred in 7 (6%) and 2 patients (1.7%), respectively. Two patients had a cranial neuropathy, and 4 patients had temporal lobe necrosis on radiologic imaging; they included 1 symptomatic case that occurred 4.5 years after the completion of treatment. One patient developed and recently died from necrosis of the nasopharynx after re-irradiation for local failure. There were no treatment-related deaths during or after the completion of either trial.
Prognostic Factors
Because no significant differences in any survival parameters were detected between the 2 trials, all patients were combined for an evaluation of prognostic factors. In a multivariate analysis, patients' sex and age, cycles of induction chemotherapy or CCRT, the use of a boost, and radiation techniques were not significant predictive factors for OS, PFS, LPFS, or DMFS. T and N classifications were significant prognostic factors for OS and DMFS. The N classification was significant, whereas the T classification showed a trend in predicting PFS. In addition, the number of cycles of induction chemotherapy (3 vs 2) showed a trend in predicting LRFS (Table 4) .
DISCUSSION
The long-term results of the phase 2 trials indicate that induction chemotherapy with a taxane, platinum, and 5-fluorouracil (TPF) provides a superb outcome for patients with locally advanced NPC. Specifically, with a median follow-up of 66.8 months, the 5-year OS, PFS, LPFS, RPFS, and DMFS rates for stage III NPC were 91.6%, 80.1%, 92.0%, 89.9%, and 93.0%, respectively, and those for stage IVA/B NPC were 83.1%, 66.8%, 87.2%, 87.4%, and 93.1%, respectively. There was a trend in the difference between the OS rates of patients with stage III NPC and patients with stage IVA/B NPC (91.6% vs 83.1%; P 5 .057), but the DMFS rates were nearly identical for the 2 stages (93% vs 93.1%). In multivariate analyses, both the T classification (T1/T2 vs T3/T4) and the N classification (N3 vs N0-N2) were significant in predicting OS and DMFS, and the N classification was also significant in predicting PFS. These data indicate that although T/N disease remains significant for determining the prognosis of patients with locally advanced NPC, TPF is sufficient to bring the overall outcomes of stage IVA/B disease close to the realm of stage III disease by reducing the adverse impact of subclinical metastases. The importance of TPF induction is further supported by the observation that local control might be compromised if patients receive fewer than the planned 3 cycles of this regimen because the number of induction chemotherapy cycles showed a trend for predicting LPFS.
The addition of concurrent chemotherapy significantly improved survival for patients with locally advanced NPC. Since the publication of the pivotal Abbreviations: CI, confidence interval; DMFS, distant metastasis-free survival; HR, hazard ratio; IMRT, intensity-modulated radiation therapy; LPFS, local progression-free survival; OS, overall survival; PFS, progression-free survival; RPFS, regional progression-free survival; RT, radiation therapy.
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Cancer June 15, 2017 INT0099 trial, 2 results from several randomized phase 3 trials have confirmed the improved efficacy of concurrent chemoradiation therapy, which has become the standard strategy for locally advanced NPC. 3, 4 The use of induction chemotherapy for NPC has also been studied extensively in both observational and prospective studies. However, early investigations mostly used cisplatin-based regimens with or without 5-fluorouracil (taxanes were not used), and they produced various results. In a randomized trial, Ma et al 20 showed that cisplatin-based induction chemotherapy improved event-free survival but not OS. Patients were treated with conventional radiation therapy alone without concurrent chemotherapy in that trial. Other investigations using platinum-based induction chemotherapy with or without concurrent chemotherapy resulted in similar outcomes, and no improvement in OS was demonstrated. 21 Results from multiple meta-analyses of trials conducted in the platinum and conventional radiation era unanimously indicated that induction chemotherapy could improve DFS but not OS. 1, 15 In summary, no study has previously demonstrated a clear benefit of induction platinum-based chemotherapy (with or without 5-fluorouracil and without a taxane) for the OS of patients with locally advanced NPC.
The efficacy of a taxane and platinum combination for patients with locally advanced head and neck squamous cell carcinoma was demonstrated in the TAX 323 and TAX 324 trials. OS rates were significantly improved in the arms receiving induction TP/TPF chemotherapy versus platinum and fluorouracil followed by concurrent chemoradiation or local treatment alone. In addition, approximately 33.3% of the patients treated with induction TPF chemotherapy followed by radiotherapy achieved a complete response; this rate was significantly higher than the rate of 19.9% after platinum and fluorouracil chemotherapy followed by radiation in the TAX 323 trial. The effectiveness of TP or TPF induction chemotherapy against locally advanced NPC was demonstrated in a pivotal randomized phase 2 trial initiated during the period of our single-arm phase 2 trials. Patients with locally advanced NPC were randomized to receive induction TP chemotherapy followed by CCRT or CCRT alone. Approximately 24% of the patients who received induction chemotherapy achieved a complete response at the primary disease site, and another 58.8% achieved a partial response. Furthermore, the 3-year OS rates were significantly different (94.1% vs 67.7%; P 5 .012) and favored the use of TP induction chemotherapy. 13 It is important to note that a 2-dimensional conventional radiation technique was used for patients in the aforementioned randomized phase 2 trial. IMRT has significantly improved the outcomes of patients with NPC (particularly local control). The use of TP or TPF induction chemotherapy followed by concurrent chemotherapy and IMRT has been investigated in retrospective studies but has not been addressed in a prospective fashion until this study. In 370 consecutive cases of locally advanced NPC treated with IMRT with or without concurrent chemotherapy, Lin et al 22 demonstrated that patients who received TPF induction chemotherapy achieved an OS rate of 89% at 3 years. Similarly, Ou et al 23 reported that the 5-year OS rate was 80.7% for a subgroup of locally advanced NPC patients who received induction chemotherapy (mostly with TP/TPF but a few with gemcitabinebased chemotherapy) followed by IMRT versus 71.4% for those who did not (P 5 .057). The numbers of induction chemotherapy cycles used in these 2 retrospective studies were not standardized, but most patients received 2 or 3 cycles.
We conducted these 2 trials with standard concurrent chemotherapy/IMRT after TPF-based induction chemotherapy. When the trials were designed in 2006, the long-term outcomes of NPC patients at various stages treated with IMRT with or without induction chemotherapy were not available. Five-year OS rates of 65% for patients with stage III NPC and 45% for patients with nonmetastatic stage IV NPC were achieved with conventional radiation concurrent with chemotherapy. 24, 25 Patients with nonmetastatic stage IV NPC were more likely to fail locally and distantly. 24 On the basis of these data, if patients with both stages were combined and the sample size was calculated for a single trial, the benefit of induction chemotherapy for local and distant control for patients with more advanced disease (ie, nonmetastatic stage IV) could potentially be mitigated by the benefit for patients with stage III disease. Therefore, we opted to initiate 2 parallel trials with a plan to compare the outcomes in terms of LPFS, PFS, and OS so that we could determine whether the downstaging of stage IVA/B disease with induction chemotherapy could be substantial enough to mitigate the extent of the disease.
The prevailing use of IMRT with concurrent chemotherapy has significantly improved the outcomes of patients with locally advanced NPC, especially with respect to local control. However, the reported 5-year OS rates in retrospective studies for patients with stage III and IVA/B NPC have remained suboptimal with ranges of approximately 70%to 75% and 60% to 65%, respectively, after such a combination without induction chemotherapy. 17, 26, 27 Because most patients treated in our trials
Original Article received IMRT, our original sample size calculation, based on the OS rates from conventional radiation therapy (65% and 45% for stage III and IVA/B NPC, respectively), might have underestimated the true OS rates in the IMRT era. To validate the applicability of our data in the IMRT era, we performed a mock sample size calculation with both stages combined to verify the statistical power because no significant differences were found in long-term OS in our trials (5-year OS rate, 91.6% vs 83.1%; P 5 .059). When a 5-year OS rate of 75% was used for stage III and IVA/B NPC patients treated with concurrent IMRT/chemotherapy as a baseline, 106 patients were needed to demonstrate a 10% improvement with a type I error rate of 5% and with a power of 80%.
Although the retrospective sample size calculation as such could not be used as the basis for reporting a prospective trial, the 5-year OS rate of 87.0% in our entire cohort of patients suggests the efficacy of TPF-based induction chemotherapy in improving long-term OS for patients with locally advanced NPC when IMRT is used.
Because of the encouraging results of our interim results and those reported by Hui et al, 13 a multicenter, randomized phase 3 trial designed to confirm the efficacy of TPF-based induction chemotherapy in the management of locally advanced NPC was initiated on the basis of our reported regimen after the publication of our interim results. 28 The results of that trial were recently reported. 29 Failure-free survival at 3 years was significantly improved after TPF-chemotherapy followed by CCRT versus CCRT alone. However, no significant improvement in OS was observed. The 3-year failure-free survival rate of 80% for patients who received induction TPF chemotherapy was nearly identical to the PFS reported in our series at the 3-year follow-up. The authors concluded that further follow-up would be needed for the long-term effectiveness of TPF-based induction chemotherapy.
Despite these encouraging results, the optimal induction chemotherapy combination has not been identified. Results from retrospective studies have suggested that gemcitabine is an effective agent in the treatment of NPC when it is used before definitive radiotherapy. 30 In a well-designed randomized phase 2/3 trial recently reported by the National Cancer Center of Singapore, 172 patients with locally advanced NPC were randomly assigned to receive either the gemcitabine, carboplatin, and paclitaxel (GCP) regimen followed by concurrent IMRT/cisplatin or concurrent IMRT/cisplatin without induction chemotherapy. 31 No difference in 3-year OS (94.3% vs 92.3%), DFS (74.9% vs 67.4%),or DMFS (83.8% vs 79.9%) was found between the 2 arms. Despite these superb survival data at 3 years, the Kaplan-Meier estimate of OS at 5 years was approximately 75% for both arms, and the estimated 5-year DFS and DMFS rates were approximately 60% and 80%, respectively. The authors thought that the significantly lower dose intensity of concurrent cisplatin used in the GCP arm might explain the lack of significance between the 2 groups of patients. Nevertheless, when it was used with concurrent chemotherapy/IMRT, GCP-based induction chemotherapy did not improve OS for patients with locally advanced NPC.
Multivariate analyses of our series indicate that advanced T disease and advanced N disease are important prognosticators for predicting OS, PFS, and DMFS but not LRFS and RPFS. Previously, Lee et al 32 reported that 5 or more cycles of chemotherapy concurrent with radiotherapy (non-IMRT) were suggested to be a significant factor for an improved outcome in comparison with less intense chemotherapy. However, a multivariate analysis of our cohorts indicated that with induction chemotherapy and IMRT, the number of concurrent chemotherapy cycles (>5 vs 4) was not a significant prognostic factor for OS or other outcomes. Nevertheless, our results also showed that 3 cycles of TPF induction chemotherapy improved LPFS in comparison with 2 cycles (P 5 .073). In addition, although nearly 12% and 33% of the patients did not complete all 3 cycles of induction and 5 or more courses of concurrent chemotherapy, respectively, all patients completed IMRT as planned. We attribute such compliance with radiotherapy to the reduced adverse effects from precision radiation. As such, one of the potential solutions is to use less intense concurrent chemotherapy with IMRT for the purpose of reducing local treatment-induced adverse effects while maintaining local/regional control after more aggressive and effective induction chemotherapy for subclinical metastatic foci. However, such a strategy requires further investigation before it can be considered for clinical practice.
Aggressive treatment strategies such as combined chemotherapy and IMRT have significantly improved the prognosis. Although patients in our trials tolerated the combined regimens well, with the improved long-term survival rates, treatment-induced late toxicities become a more substantial health hazard and a challenge for oncologists. One of the potential solutions for reducing adverse effects is to use newer concurrent agents with IMRT that may produce fewer toxicities while maintaining efficacy. The results from a randomized clinical trial, recently reported in abstract form, that compared the toxicity profiles of concurrent cisplatin and nimotuzumab (a humanized anti-epidermal growth factor receptor antibody) indicated that nimotuzumab produced similar outcomes in terms of local control, DFS, DMFS, and OS but produced less acute hematologic and gastrointestinal toxicities. 33 In addition, the utilization of more accurate radiation technology, such as proton or carbon-ion radiotherapy, may further reduce radiation-induced local toxicities while providing the potential for increased radiation dose escalation for better local control. The dosimetric and clinical advantages of proton and carbon-ion radiotherapy have been demonstrated previously for the management of locally recurrent NPC. 34, 35 However, few full articles have been published on the clinical outcomes of the use of particle therapy for newly diagnosed NPC. 36 In conclusion, TPF-based induction chemotherapy followed by concurrent IMRT and chemotherapy produced superb outcomes for patients with stage III or IVA/ B NPC. With a median follow-up of 67 months, the 5-year OS, PFS, LPFS, RPFS, and DMFS rates were 91.6%, 80.1%, 92.0%, 89.9%, and 93.0%, respectively, for stage III NPC patients and 83.1%, 66.8%, 87.2%, 87.4%, and 93.1%, respectively, for stage IVA/B NPC patients. Advanced T disease and advanced N disease were significant predictive factors for OS, PFS, and DMFS in a multivariate analysis, and no significant differences in LPFS or RPFS were found between the 2 stages; therefore, future studies of NPC should still focus on more effective or aggressive management of patients who potentially harbor subclinical metastases while reducing treatment-induced toxicities because long-term survival after definitive treatment is expected for most patients with locally advanced NPC.
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